Products for Research Use Only

Pimozide-d4-1

CAT: 0804-HY-12987S2-01Size: 100 µgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-12987S2-01Size:100 µg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Pimozide-d4-1 is the deuterium labeled Pimozide. Pimozide is a dopamine receptor antagonist, with Kis of 1.4 nM, 2.5 nM and 588 nM for dopamine D2, D3 and D1 receptors, respectively, and also has affinity at α1-adrenoceptor, with a Ki of 39 nM; Pimozide also inhibits STAT3 and STAT5[1][2][3][4].
Product Name Alternative
R6238-d4-1
UNSPSC
12352005
Target
Adrenergic Receptor; Dopamine Receptor; Parasite; STAT
Type
Isotope-Labeled Compounds
Related Pathways
Anti-infection; GPCR/G Protein; JAK/STAT Signaling; Neuronal Signaling; Stem Cell/Wnt
Applications
Metabolism-protein/nucleotide metabolism
Field of Research
Cancer; Endocrinology; Neurological Disease
Purity
99.68
Solubility
10 mM in DMSO|DMF : ≥ 30mg/mL|DMSO : ≥ 30mg/mL|Ethanol : ≥ 3mg/mL
Smiles
O=C1NC2=C([2H])C([2H])=C([2H])C([2H])=C2N1C3CCN(CCCC(C4=CC=C(F)C=C4)C5=CC=C(F)C=C5)CC3
Molecular Formula
C28H25D4F2N3O
Molecular Weight
465.57
References & Citations
[1]Ybema CE, et al. Adrenoceptors and dopamine receptors are not involved in the discriminative stimulus effect of the 5-HT1A receptor agonist flesinoxan. Eur J Pharmacol. 1994 Apr 21;256 (2) :141-7. |[2]Cai N, et al. The STAT3 inhibitor pimozide impedes cell proliferation and induces ROS generation in human osteosarcoma by suppressing catalase expression. Am J Transl Res. 2017 Aug 15;9 (8) :3853-3866. eCollection 2017. |[3]Erik A. Nelson, et al. The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors. Blood. 2011 Mar 24; 117 (12) : 3421-3429. |[4]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-223.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Isotope-Labeled Compounds
Clinical Information
No Development Reported